US 12,286,463 B1
Interleukin 18 (IL-18) variants and fusion proteins comprising same
John K. Cini, Blairstown, NJ (US); and Susan J. Dexter, Rye, NH (US)
Assigned to SONNET BIOTHERAPEUTICS, INC., Princeton, NJ (US)
Filed by Sonnet BioTherapeutics, Inc., Princeton, NJ (US)
Filed on Nov. 15, 2024, as Appl. No. 18/948,648.
Application 18/948,648 is a continuation of application No. 18/740,390, filed on Jun. 11, 2024, granted, now 12,134,635.
Claims priority of provisional application 63/658,322, filed on Jun. 10, 2024.
Claims priority of provisional application 63/616,148, filed on Dec. 29, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/54 (2006.01); C07K 16/18 (2006.01); C12N 15/64 (2006.01)
CPC C07K 14/54 (2013.01) [C07K 14/5434 (2013.01); C07K 16/18 (2013.01); C12N 15/64 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01)] 12 Claims
 
1. A variant human IL-18 (hIL-18) protein comprising a substitution at amino acid positions Y1, M51, M60, S105, and D110, relative to human wild-type IL-18 (SEQ ID NO:2), wherein the substitutions are Y1W, Y1K, M51Y, M51S M60W, S105E, and D110Y.